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Abstract. Pancreatic cancer is one of the most aggressive, 
heterogeneous and fatal type of human cancers for which 
more effective therapeutic agents are urgently needed. Here, 
we investigated the sensitivity of a panel of seven human 
pancreatic cancer cell lines (HPCCLs) to treatment with 
various tyrosine kinase inhibitors (TKIs), cyclin-dependent 
kinase (CDK) inhibitors, an inhibitor of STAT3 stattic, and 
a cytotoxic agent gemcitabine both as single agents and 
in combination. The membranous expression of various 
receptors and the effect of selected agents on cell cycle 
distribution, cell signaling pathways and migration was 
determined using flow cytometry, western blot analysis 
and scratch wound healing assays, respectively. While 
the expression of both HER-3 and HER-4 was low or 
negative, the expression of EGFR and HER2 was high or 
intermediate in all HPCCLs. Of all the agents examined, 
the CDK1/2/5/9 inhibitor, dinacicilib, was the most potent 
agent which inhibited the proliferation of all seven HPCCLs 
with IC50 values of ≤10 nM, followed by SRC targeting TKI 
dasatinib (IC50 of ≤258 nM), gemcitabine (IC50 of ≤330 nM), 
stattic (IC50 of ≤2 µM) and the irreversible pan‑HER TKI 
afatinib (IC50 of ≤2.95 µM). Treatment with afatinib and 
dasatinib inhibited the ligand-induced phosphorylation of 
EGFR and SRC respectively. Statistically significant asso-
ciations were found between HER2 expression and response 
to treatment with the ALK/IGF-IR/InsR inhibitor ceritinib 
and fibroblast growth factor receptor (FGFR)1/2/3 inhibitor 
AZD4547, HER3 and IGF-IR expression and their response 
to treatment with TKIs targeting HER family members 
(erlotinib and afatinib), and c‑MET and ALK7 expression 
and their response to treatment with stattic. Interestingly, 
treatment with a combination of afatinib with dasatinib and 
gemcitabine with dasatinib resulted in synergistic tumor 
growth inhibition in all HPCCLs examined. In contrast, 
the combination of afatinib with dinaciclib was found to 
be antagonistic. Finally, the treatment with afatinib, dasat-
inib and dinaciclib strongly inhibited the migration of all 
HPCCLs examined. In conclusion, the CDK1/2/5/9 inhibitor 
dinaciclib, irreversible pan-HER TKI afatinib and SRC 
targeting TKI dasatinib were most effective at inhibiting the 
proliferation and migration of HPCCLs and the combination 
of afatinib with dasatinib and gemcitabine with dasatinib 
led to synergistic tumor growth inhibition in all HPCCLs 
examined. Our results support further investigation on the 
therapeutic potential of these combinations in future clinical 
trials in pancreatic cancer.
Introduction
Pancreatic cancer is one of the deadliest types of human 
cancer. Globally, there were an estimated 458,918 new cases 
of pancreatic cancer and 432,242 pancreatic cancer deaths in 
2018 (1,2). In the USA, there will be an estimated 57,600 new 
cases of pancreatic cancer and 47,050 pancreatic cancer-related 
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deaths in 2020 (3). Several modifiable risk factors i.e., 
smoking, alcohol, obesity, Helicobacter pylori infection and 
non‑modifiable factors such as age, sex (male predominance), 
race/ethnicity (higher incidence in black population), blood 
group (A, B and AB), family history and genetic susceptibility 
(e.g., BRCA2 mutation) have been identified that increase 
the likelihood of developing pancreatic cancer (2-6). Despite 
preventive measures (e.g., avoidance of above risk factors) 
and numerous advances in the imaging technologies and the 
development of cancer therapeutics in the past few decades, 
around 80-85% of patients with pancreatic cancer have an 
unresectable tumor at the time of presentation with the 5-year 
survival rate of only 9% (2-6). Therefore, there is an urgent 
need not only to identify biomarkers of diagnostic, prognostic 
and predictive value but also to develop more effective and less 
toxic therapeutic interventions.
Growth factor receptor tyrosine kinases (RTKs) with 
tyrosine kinase activity and their downstream cell signaling 
molecules are important not only in normal development but 
also when aberrantly expressed or activated in the pathogenesis 
of human cancers and therapeutic targets. One such example 
is the human epidermal growth factor receptor subfamily 
(also called EGFR or ErbB family) which consists of four 
members; ErbB1/HER1/(also called EGFR), ErbB2/HER2, 
ErbB3/HER3 and ErbB4/HER4 (7). Upon ligand binding 
(EGF, AR and TGFα for EGFR, HB-EGF, BTC, Epiregulin 
for EGFR/HER4 and NGR1-4 for HER3/4) conformational 
changes in the extracellular domain of ErbB receptor are 
induced resulting in the formation of homodimers or heterodi-
mers between ErbB family members. This leads to an auto 
and/or trans-phosphorylation of C-terminal region of the 
intracellular tyrosine kinase domain leading to the activation 
of various downstream signaling pathways such as PI3K-AKT, 
RAS/RAF/MAPK, JAK‑STAT and PLC-γ1 that regulates 
proliferation, metabolism, angiogenesis, cell progression and 
survival (7-9). In some studies, aberrant expression and acti-
vation of HER-mediated signaling has been associated with 
tumor aggressiveness and a poorer prognosis in patients with 
pancreatic cancer (7,10-13). However, of the HER inhibitors, 
only the reversible EGFR‑specific erlotinib has been approved 
by the US FDA for the treatment of locally advanced, unresect-
able or metastatic pancreatic cancer when used in combination 
with gemcitabine (14). While erlotinib treatment improved 
patient survival, the duration of response is usually short with 
both primary and secondary resistance being the major causes 
of the treatment failure (14). Therefore, it is imperative to 
discover more effective and less toxic therapeutic agents for 
the treatment of patients with pancreatic cancer (7).
In addition to the HER family members, deregulation of 
other subfamilies of RTKs including insulin-like growth factor 
1 receptor (IGF‑IR), c‑MET and anaplastic lymphoma kinase 
(ALK) as well as non-RTKs including SRC have been reported 
in pancreatic cancer (7,15-19), For example, overexpression 
and activation of IGF-IR has been associated with the aggres-
siveness, poor prognosis and resistance to anti-HER targeted 
therapy in some patients with pancreatic cancer (15). Increased 
SRC activity has also been reported in more than 60% of 
pancreatic cancers resulting in increased crosstalk between 
tumor cells and the surrounding stroma ultimately leading to 
increased tumorigenesis, metastasis and a poorer response to 
therapy (20-22). Preclinical studies have shown the effective-
ness of dasatinib in treating patients with pancreatic cancer; 
however, it has failed to demonstrate significant results in 
clinical trials (23) suggesting that dasatinib monotherapy may 
not be of therapeutic value in patients with pancreatic cancer. 
Therefore, further studies of such agents in combination with 
other agents are warranted.
In recent years, both the heterogeneous nature of pancreatic 
cancer and its complex biology and tumor microenvironment 
have been associated with resistance to therapy (24-26). In 
our previous study, we demonstrated that the second genera-
tion pan-HER family blocker, afatinib, was more effective 
than the first generation EGFR TKIs erlotinib and gefitinib in 
inhibiting the growth of human pancreatic cancer cells (27). 
We also reported the superiority of afatinib when used in 
combination with the IGF-IR inhibitor NVP-AEW541 (15). 
The aim of this study was to investigate the sensitivity of 
a panel of human pancreatic cancer cell lines established 
from patients at different stages of the disease to treatment 
with agents targeting various growth factor receptors such 
as HER family members (afatinib and erlotinib), c‑MET 
(crizotinib and capmatinib), ALK (ceritinib and brigatinib), 
IGF-IR (NVP-AEW742 and linsitinib), SRC family (dasat-
inib, bosutinib and ponatinib), CDK inhibitors (palbociclib 
and dinaciclib), STAT3 inhibitor (stattic) and cytotoxic agent 
(gemcitabine) both as single agents and/or in combination. 
We also investigated the association between the cell surface 
expression of various growth factor receptors and their 
response to treatment with the above agents. Furthermore, 
the effect of selected agents on the phosphorylation of HER 
receptors and subsequent downstream signaling molecules, 
cell cycle distribution and migration of human pancreatic 
cancer cell lines were determined.
Materials and methods
Tumor cell lines. A panel of seven human pancreatic cancer 
cell lines (HPCCLs) was used in this study including BxPC-3, 
Capan‑1, FA‑6, Panc‑1, Mia‑Paca‑2, Hs766T and CF‑PAC‑1. 
All cell lines were cultured routinely at 37˚C in a humidi-
fied atmosphere (5% CO2) as described previously (15,28). 
BxPC‑3, Capan‑1 and FA‑6 were cultured in RPMI‑1640 
medium (Sigma‑Aldrich; Merck KGaA), Panc‑1, Mia‑Paca‑2 
and Hs766T were cultured in Dulbecco's modified Eagle's 
medium (DMEM) (Merck) and CF‑PAC‑1 was cultured in 
Iscove's modified medium each supplemented with 10% 
fetal bovine serum (FBS) (heat inactivated) (Sigma-Aldrich; 
Merck KGaA), antibiotics penicillin (50 µg/ml), strepto-
mycin (50 µg/ml) and neomycin (50 µg/ml) (Sigma-Aldrich; 
Merck KGaA). RPMI‑1640 and Iscove's modified Dulbecco's 
medium were supplemented with 2 and 8 mM L‑glutamine 
(Sigma‑Aldrich; Merck KGaA) respectively.
Tyrosine kinase inhibitors and antibodies. Gemcitabine and 
crizotinib were purchased from Healthcare at Home (Burton 
on Trent, UK) and Tocris (Avonmouth, UK), respectively. 
Afatinib, NVP-AEW742, stattic, brigatinib, linsitinib, ceri-
tinib, crenolanib, ponatinib, dasatinib, bosutinib, AZD4547, 
palbociclib, erlotinib and dinaciclib were all purchased 
from Selleckchem (Europe Ltd. UK). The antibodies for 
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flow cytometry including mouse anti‑EGFR (HM43.16B) 
and anti‑HER2 (HM50.67A) were raised in‑house against 
the external domain of these receptors (29) whereas mouse 
anti‑HER3 (MAB3481), anti‑HER4 (MAB11311), ALK7 
(MAB77491), HGF R /c‑MET (MAB3582), PDGFRα 
(MAB1264), PDGFRβ (MAB1263) and IGF‑IR (MAB391) 
were purchased from R&D Systems (Europe Ltd. UK) and 
Insight Biotechnology (Middlesex, UK), respectively. The 
anti‑mouse IgG FITC‑conjugated STAR9B was purchased 
from Serotec Ltd. (Oxford, UK). The antibodies for western 
blot analysis including mouse anti-EGFR monoclonal anti-
body (mAb) (clone F4) and phosphor-Tyr-100 were obtained 
from Merck (Dorset UK) and Cell Signaling Technology, Inc. 
(Hitchin, UK) respectively. The rabbit anti-phospho-EGFR 
(Tyr 1068), MAPK, phospho‑MAPK (Tyr204), Akt, 
phospho-AKt (Ser473), STAT3, phospho-STAT3 (Tyr705), 
SRC, phospho-SRC (Tyr416), phospho-IGF-IR and β-actin 
were all obtained from Cell Signaling Technology, Inc. 
Both the goat anti-mouse IgG IRDye 800CW and donkey 
anti-rabbit IgG IRDye 680RD was purchased from LI-COR 
Ltd. (Cambridge, UK).
Flow cytometry. The surface expression of various growth 
factor receptors on HPCCLs was accessed by flow cytometry 
as described previously (27,30). Approximately 1x106 cells 
suspended in 2% FBS medium were added to 1.5 ml Eppendorf, 
centrifuged (254 x g for 3 min), washed once with cold PBS 
and incubated with or without 10 µg/ml of the primary 
antibody by rotation at 4˚C for 1 h. Following that, the cells 
were washed thrice with 1 ml of cold PBS by centrifugation 
(254 x g for 3 min) and incubated with secondary antibody 
STAR9B (1:200 dilution) by rotation at 4˚C for 1 h. Finally, 
the cells were washed thrice with cold PBS by centrifuga-
tion and re‑suspended in 1 ml of FACS flow buffer (Becton 
Dickinson UK, Ltd., Oxford). FACS analysis was carried out 
using Cell Quest Pro software (Becton Dickinson, version 
6.0). A minimum of 10,000 events were measured through 
excitation of argon laser at 488 nm using an FITC detector 
(525 nm) as part of the BD FACS Calibur Flow cytometer 
(BD Biosciences).
Growth inhibition studies. In order to determine the effect of 
various agents on the proliferation of HPCCLs, sulforhodamine 
B (SRB; Sigma‑Aldrich; Merck KGaA) colorimetric assay 
was used as described previously (27). Briefly, 5x103 cells/well 
were seeded in 100 µl of growth medium supplemented with 
2% FBS in a 96‑well plate and incubated at 37˚C (in a humidi-
fied atmosphere in 5% CO2). Following a 4-h incubation, ‘time 
zero' plate (representing the number of cells prior to treatment) 
was fixed with 10% trichloroacetic acid (Fisher Scientific, 
Loughborough, UK) for 1 h at room temperature, washed 
thrice with tap water and left to air dry overnight. For other 
plates, 100 µl of doubling dilutions of agents were added to 
each well in triplicate and incubated at 37˚C until the controls 
(medium only) became confluent. These plates were then fixed 
as mentioned above, stained with 0.04% (w/v) SRB in 1% 
acetic acid for 1 h, washed thoroughly with 1% acetic acid and 
left to air dry overnight. The stained cells were solubilized 
with 100 µl/well of 10 mM Tris‑Base and the absorbance of 
each well was measured at 565 nm using an Epoch plate reader 
(Thermo Fisher Scientific, Inc.). Growth as a percentage of 
control was determined using the following formula: 
where X is the absorbance of the drug-treated well at 565 nm, 
Y is the absorbance prior to treatment at 565 nm and Z is the 
absorbance of the untreated cells at 565 nm.
The 50% inhibitory concentration of each agent (IC50) was 
calculated using the non‑linear least squares curve fitting (four 
parameter analysis, log (inhibitor) vs response, variable slope) 
using Gen5 software (BioTeck, UK).
Cell cycle distribution analysis. The effect of selected 
agents including inhibitors of HER family members, CDK, 
SRC, STAT3 and cytotoxic agent on the cell cycle distribu-
tion of HPCCLs was investigated using flow cytometry. 
Approximately, 0.5x106 cells/well were seeded in 5 ml of 2% 
FBS medium with or without drugs at IC70 and incubated 
at 37˚C until the control wells (no drugs) became almost 
confluent. Following that, the cells were harvested by trypsin-
ization and pooled with their respective supernatants, washed 
once with cold PBS by centrifugation (264 x g for 4 min) and 
fixed with 70% ice‑cold ethanol for minimum of 3 h at ‑20˚C. 
The cells were collected by centrifugation (450 x g for 5 min) 
washed thrice with cold PBS and stained with Guava cell 
cycle reagent (Luminex). Cells were then run through a Guava 
EasyCyte™ flow cytometer (Luminex Corp.) where 5,000 
events were recorded by excitation with a argon laser (488 nm) 
using Yellow‑B fluorescence (583/26 nm) and analyzed using 
Incyte™ soft 3.3 (Luminex Corp.).
Determination of the combination index. The effect of selected 
agents on the growth of HPCCLs when used in combination 
was assessed using SRB assay as described previously (27). 
For each combination, two agents (TKIs or cytotoxic agent) 
were mixed at their respective 4x IC50 value (determined 
previously as a single agent) followed by eight doubling dilu-
tions. Data analysis was performed using Calcusyn software 
(Biosoft, UK) and interpreted as follow: <0.9=synergistic 
effect, 0.9-1.1=additive effect, >1.1=antagonistic effect.
Western blot analysis. The effect of various agents on 
downstream signaling molecules of BxPC-3 and Capan-1 
cells was investigated using western blot analysis. Briefly, 
0.5x106 cells/well were grown in 5 ml of 10% FBS RPMI‑1640 
medium in 6‑well plate to near confluency. Cells were washed 
once with 5 ml of 0.5% FBS RPMI‑1640 medium and incu-
bated at 37˚C with the desired drug at a final concentration of 
400 nM (or no inhibitor/medium only as a negative control) 
in 5 ml of fresh 0.5% FBS RPMI‑1640 medium for 1 h. After 
that, the cancer cells were incubated for a further 15 min with 
EGF, HB-EGF or IGF-II or no ligand. The cells were then 
washed once with PBS and lysed with 400 µl of preheated lysis 
buffer (Invitrogen; Thermo Fisher Scientific, Inc.) containing 
protease inhibitor cocktail (Sigma‑Aldrich; Merck KGaA) and 
homogenized using 25x5/8' gauge needles in order to reduce 
its viscosity. Protein samples (30 µg) were separated on 4‑12% 
Bis‑Tris gel (Invitrogen; Thermo Fisher Scientific, Inc.) using 
the XCell II Surelock Mini‑Cell system (Invitrogen; Thermo 
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Fisher Scientific, Inc.) and transferred onto Immobilon‑FL 
PVDF membranes (Merck) using XCell II Mini‑Cell Blot 
Module kit (Invitrogen; Thermo Fisher Scientific, Inc.). The 
PVDF membranes were probed with various antibodies at the 
manufacturer's recommended dilutions and visualized using 
the LI-COR Image Studio software (version 1.x-2.x).
Scratch wound healing assay. The effect of selected agents 
on the migration of HPCCLs was investigated using scratch 
wound healing experiment. Briefly, 1x105 cells/100 µl of 10% 
FBS medium per well were seeded in a corning CELLBIND™ 
96‑well clear flat bottom sterile plate (Sigma‑Aldrich; Merck 
KGaA). Following 24 h of incubation at 37˚C, wounds were 
created using a wound maker, carefully aspirating medium 
from each well. After washing with PBS, cells were treated 
with 200 µl of 10% FBS medium containing various drugs or 
medium only as positive control. The plate was then placed 
onto the IncuCyte Zoom® instrument at 37˚C for 72 h where 
cells were analyzed every 3 h using Incucyte Zoom® software 
(Essen Bioscience, version 2018A).
Statistical analysis. The statistical analysis was carried out 
using SPSS software (IBM®, SPSS statistics version 26). 
Linear regression analysis was used to assess the relation-
ship between the expression of HER family members and 
response to treatment with various TKIs, CDK inhibitor, 
STAT3 inhibitor and cytotoxic agent. The effect of selected 
agents on the migration of pancreatic cancer cell lines were 
tested by paired t‑test analysis. A P‑value of ≤0.05 was 
considered to be statistically significant and an R2 value 
closer to 1 showed the reliability of the association between 
the IC50 value of each drug and expression level of each 
marker. All statistical analyses were carried out using SPSS 
statistics 26 (SPSS Inc.).
Results
Cell surface expression of various growth factor receptors in 
pancreatic cancer cell lines. We determined the expression 
level of various membrane bound growth factor receptors 
including HER family members, IGF‑IR, c‑MET and ALK7 
in seven HPCCLs using flow cytometry and the results are 
represented as mean fluorescence intensity (MFI) and histo-
grams (Table I, Fig. 1). Most cell lines were found to have high 
expression for EGFR and moderate expression for HER2. In 
comparison to control EGFR-overexpressing breast cell line 
MDA‑MB‑468 (MFI=806), the MFI values for EGFR expres-
sion in our panel ranged from moderate (Mia‑Paca‑2, MFI=21.1) 
to high (Hs766T, MFI=236.9). Similarly, in comparison to 
control HER2-overexpressing ovarian cancer cell line SKOV3 
(MFI=385), the MFI values for HER2 expression in our panel 
of HPCCLs ranged from low (Hs766T, MFI=11.2) to moderate 
(Capan‑1, MFI=33.1). The expression level of HER3 and HER4 
was undetectable to very low in most of the cell lines. Finally, 
in comparsion to the IGF-IR and ALK7-positive breast cancer 
cell lines MDA‑MB231 (MFI of 23 and 20, respectively) and 
c‑MET positive MDA‑MB468 (MFI=35), our panel of human 
pancreatic cancer cells had low to moderate level of expres-
sion with BxPC-3 cells having the highest expression of both 
IGFIR (MFI=28.4) and ALK (MFI=50.2) and Hs766T having 
the highest level of expression of C‑MET with an MFI value of 
50.8 respectively (Table I).
Growth response of human pancreatic cancer cell lines to 
treatment with various TKIs, CDK inhibitors, STAT3 inhibitor 
and cytotoxic agent. The effect of various agents on the growth 
of HPCCLs was determined using SRB assay and the results 
are expressed as IC50 (Table II, Fig. 2). Of all the agents tested, 
the CDK1/2/5/9 inhibitor dinaciclib was the most potent agent 
inhibiting the growth of all seven cell lines with the IC50 values 
of ≤10 nM. This was followed by the Abl/Src/c-kit TKI dasat-
inib with IC50 values of 13 nM (CF‑PAC1) to 258 nM (Panc‑1); 
gemcitabine with IC50 of ≤330 nM; the STAT3 inhibitor, static, 
with IC50 values of 0.74 µM (Panc‑1) to 2 µM (BxPC‑3) and 
the irreversible pan-HER TKI afatinib with IC50 of 27 nM 
(BxPC‑3) to 2.95 µM (FA‑6). The morphology of BxPC‑3 
cells following treatment with the above agents compared to 
the control are presented in Fig. 3. The effect of c‑MET/ALK 
inhibitor, crizotinib, ALK/IGF-IR/InsR inhibitor ceritinib, 
Abl/PDGFRα/VEGFR2/FGFR1/Src inhibitor ponatinib and 
Src/Abl inhibitor, bosutinib, on the growth of all HPCCLs 
was found to be moderate (Table II). However, treatment with 
the PDGFRα/β inhibitor crenolanib, FGFR1/2/3 inhibitor 
AZD4547, c‑MET inhibitor capmatinib, IGF‑IR inhibitor 
NVP-AEW742, and IGF-IR/InsR inhibitor brigatinib had 
minimum to no inhibitory effect on HPCCLs (Table II).
Cell cycle distribution analysis. The effect of various agents 
on the cell cycle distribution of four HPCCLs was deter-
mined using flow cytometry and the results are summarized 
in Table III. Treatment with afatinib, dinaciclib, dasatinib, 
stattic and gemcitabine increased the percentage of cells in the 
sub-G1 phase (apoptotic/dead cells) with subsequent reduction 
in the G0/G1 phase. Furthermore, treatment with afatinib and 
dasatinib increased cells in the S and G2/M phase whereas 
treatment with dinaciclib and gemcitabine increased cells in 
the S-phase in most of the cell lines examined. The representa-
tive flow cytometry plots of cell cycle distribution of BxPC‑3 
cells following treatment with these agents is shown in Fig. S1.
Afatinib and dasatinib blocks the phosphorylation of EGFR 
and SRC respectively. Next we investigated the effects of 
treatment with afatinib, dinaciclib, dasatinib and stattic on 
the phosphorylation of growth factor receptors and down-
stream cell signaling molecules in BxPC-3 and Capan-1 
cells. As expected, afatinib blocked the ligand-induced 
phosphorylation of tyrosine and phosphorylation of EGFR 
at position 1,068 which in turn resulted in reduction in the 
phosphorylation of downstream signaling molecules such 
as MAPK and AKT in both cell lines examined (BxPC‑3 
and Capan-1) (Fig. 4A and B). Treatment with dasatinib 
alone was accompanied by the EGF, HB-EGF and IGF-II 
induced phosphorylation of SRC. However, no phosphory-
lation of the IGF-IR was evident following treatment with 
EGF, HB-EGF and IGF-II in these two cancer cell lines 
(data not shown).
Synergistic and antagonistic effect of various drug combina-
tions in pancreatic cancer cell lines. The combined effect of 
various agents including afatinib, dinaciclib, dasatinib, stattic 
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Figure 1. The membrane bound expression level of various growth factor receptors determined by flow cytometry in human pancreatic cancer cell lines repre-
sented as histograms. EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; c‑MET, mesenchymal‑epithelial transition 
factor; IGF-IR, insulin-like growth factor 1 receptor; ALK7, anaplastic lymphoma kinase 7.
Table I. Surface expression of various growth factor receptors in human pancreatic cancer cell lines.
 Mean fluorescence intensity
 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Pancreatic cancer cell lines Control EGFR HER2 HER3 HER4 IGF‑IR C‑MET ALK7
BxPC-3 (primary tumor) 4.1±0.3 195.6±36.1 22.5±4.5 12.7±1.3 11.1±0.2 28.4±2.2 40.5±5.3 50.2±9.7
Capan-1 (liver metastasis) 5.3±0.4 63.6±6.8 33.12±3.2 8.4±0.5 7.5±0.4 22.3±0.2 23.5±0.9 24.3±0.6
FA-6 (unknown) 4.1±0.5 133.6±11.5 13.9±0.3 8.67±0.1 6.48±0.5 9.1±0.4 17.2±0.5 24.0±0.3
Panc-1 (primary tumor) 5.0±0.5 232.6±4.4 32.3±4.6 7.37±0.4 11.41±0.1 20.3±1.5 5.0±0.0 23.5±1.3
Mia‑Paca2 (primary tumor) 4.9±0.1 26.0±9.1 22.6±0.5 5.26±0.2 7.93±0.3 16.8±0.5 6.0±0.2 6.8±0.0.4
Hs766T (lymph node metastasis) 4.1±0.6 241±4.5 11.2±0.4 10.4±0.1 15.5±0.4 16.1±0.8 50.8±7.2 37.5±3.0
CF-PAC1 (liver metastasis) 4.5±0.5 96.7±7.8 48.3±1.4 18.1±0.8 9.52±0.2 26.2±3.2 38.8±4.2 26.3±0.6
Controls        
MDA‑MB‑468  4.4±0.3 806.1±0.5 N/A N/A N/A N/A 35.3±1.7 N/A
SKOV3 (ovarian) 4.1±0.2 N/A 385.2±0.4 N/A N/A N/A N/A N/A
MDA‑MB‑231  4.0±0.3 N/A N/A N/A N/A 23.2±0.6 N/A 20.3±1.9
N/A, not available. MDA‑MB‑231, MBA‑MB‑468 and SKOV3 cell lines were used as positive controls. EGFR, epidermal growth factor 
receptor; HER, human epidermal growth factor receptor; IGF-IR, insulin-like growth factor 1 receptor.
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and gemcitabine on the growth of HPCCLs was investigated. 
Only treatment with a combination of dasatinib with afatinib 
or dasatinib in combination with gemcitabine led to synergistic 
growth inhibition of four HPCCLs (Table IV). In contrast, 
treatment with a combination of afatinib with dinaciclib was 
found to be antagonistic in all of four HPCCLs examined 
(Table IV). Finally, treatment with other drug combinations 
resulted in mixed effects in all cell lines examined (data not 
shown).
Linear regression analysis. The association between the 
expression level of various growth factor receptors and their 
response to treatment with various agents was assessed using 
SPSS software (Table V). There was no correlation between 
expression level of EGFR and the response to treatment with 
various agents. However, there were some statistically signifi-
cant associations between HER2 expression and the response 
to treatment with ALK/IGF-IR/InsR inhibitor ceritinib 
(R2=0.698, P=0.019) and the FGFR1/2/3 inhibitor AZD4547 
(R2=0.751, P=0.012); HER3 expression and the response to 
treatment with HER family targeting TKI erlotinib (R2=0.830, 
P=0.004) and afatinib (R2=0.599, P=0.041); IGF-IR expres-
sion and the response to treatment with erlotinib (R2=0.608, 
P=0.039) and afatinib (R2=0.672, P=0.024). In addition, a 
statistically significant association was found between c‑MET 
expression and the response to treatment with STAT3 inhibitor 
stattic (R2=0.809, P=0.006) and SRC/Abl inhibitor bosutinib 
(R2=0.747, P=0.012) and finally between ALK7 expression 
and the response to treatment with STAT3 inhibitor stattic 
(R2=0.682, P=0.022). HER4 was not tested due to its negative 
expression in all cell lines.
Effect of selected agents on the migration of pancreatic cancer 
cell lines. The effect of selected agents on the migration of four 
HPCCLs was determined using scratch wound healing assay 
and the results at time points 6, 12 and 24 h are summarized in 
Fig. 5A. As an example, the effect of these agents on the migra-
tion of BxPC-3 cells at 24 h is shown in Fig. 5B. In comparison to 
Figure 2. Effect of doubling dilutions of TKIs targeting HER family members and SRC family kinases, inhibitors of CDK and STAT3 and cytotoxic agent 
on the growth of human pancreatic cell lines. Cells were grown in 2% FBS growth medium with or without drugs until control cells (only medium) were 
confluent. Each point represents the mean ± SD of the triplicate sample. TKIs, tyrosine kinase inhibitors; HER, human epidermal growth factor receptor; CDK, 
cyclin-dependent kinase; STAT3, signal transducer and activator of transcription 3.
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positive control (i.e., no treatment, 10% FBS medium only) most 
drugs inhibited the migration of HPCCLs with SRC targeting 
TKI dasatinib, and the CDK inhibitor dinaciclib and the irrevers-
ible pan-HER TKI afatinib being most effective (Fig. 5A and B).
Table III. Effect of various agents on the cell cycle distribution of human pancreatic cancer cell lines.
Cell line/treatment Sub G1 G0/G1 S G2/M
BxPC3/    
  Control 5.28±0.36 65.65±3.54 16.70±1.65 11.63±2.60
  Afatinib 8.88±1.84 52.25±4.60 18.60±2.40 19.36±5.45
  Dinaciclib 24.30±9.93 41.36±13.85 22.75±3.26 10.76±3.23
  Dasatinib 21.51±8.26 38.57±15.23 19.52±0.37 16.57±4.55
  Stattic 39.05±11.89 38.89±8.63 15.00±0.16 6.86±0.56
  Gemcitabine 20.20±7.98 46.04±20.80 22.55±12.52 10.37±2.31
Capan-1/    
  Control 18.37±5.98 60.75±0.41 13.63±3.98 7.53±3.20
  Afatinib 44.77±15.22 44.92±11.96 8.26±3.37 2.32±1.42
  Dinaciclib 58.17±15.68 35.03±15.63 6.79±2.50 1.00±0.30
  Dasatinib 42.79±19.48 39.45±13.99 14.20±5.96 4.00±1.92
  Stattic 67.61±37.94 25.45±29.59 6.70±8.70 2.03±2.66
  Gemcitabine 62.72±18.94 32.91±17.64 4.35±3.16 0.59±0.50
FA-6/    
  Control 3.73±2.26 57.63±1.85 24.00±0.81 13.88±4.01
  Afatinib 16.60±9.44 30.99±4.25 31.47±0.33 18.79±3.44
  Dinaciclib 17.45±9.18 29.61±5.42 33.25±3.01 18.48±4.99
  Dasatinib 5.70±5.87 28.86±9.48 43.17±10.81 19.19±4.88
  Stattic 31.94±2.81 20.61±1.88 31.49±2.26 14.02±0.30
  Gemcitabine 11.86±6.78 42.07±18.45 35.83±8.05 9.47±3.11
Mia‑Paca2/    
  Control 1.82±1.85 68.67±2.14 16.46±1.59 12.63±3.25
  Afatinib 17.70±23.89 22.57±16.79 39.67±7.94 20.95±17.16
  Dinaciclib 17.58±20.83 40.94±15.47 29.90±0.51 11.69±8.92
  Dasatinib 2.10±0.36 52.91±9.14 24.93±5.55 18.68±0.49
  Stattic 24.19±33.06 32.28±25.82 22.16±10.65 20.61±1.56
  Gemcitabine 3.14±1.23 38.97±12.76 43.88±25.77 14.50±10.83
Each value is expressed as mean± SD of the gated cells.
Figure 3. Morphology of BxPC‑3 cells (A) following treatment with CDK inhibitor dinaciclib (B) SRC targeting TKI dasatinib (C) cytotoxic agent gemcitabine 
(D) the irreversible pan-HER TKI afatinib (E) and the STAT3 inhibitor stattic (F) CDK, cyclin-dependent kinase; TKI, tyrosine kinase inhibitor; HER, human 
epidermal growth factor receptor; STAT3, signal transducer and activator of transcription 3.
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Figure 4. Effect of afatinib, dinaciclib, dasatinib, stattic and NVP-AEW742 with or without ligands (EGF, HB-EGF, IGF-II) on the phosphorylation of EGFR 
and downstream cell signaling molecules including MAPK, AKT, STAT3, SRC and IGF‑IR in BxPC‑3 (A) and Capan‑1 (B) cells. The cells were cultured in 
10% FBS RPMI‑1640 medium to near confluency. Cells were washed once with 0.5% FBS RPMI‑1640 medium and incubated with selected agents (400 nM) 
for 1 h and then stimulated with 40 nM ligands (EGF, HB‑EGF and IGF‑II) for 15 min. Cells were then lysed, separated using SDS‑PAGE, transferred onto 
PDVF membranes, probed with the antibodies of interest and visualized using LI-COR software. EGF, epidermal growth factor; HB-EGF, heparin-binding 
EGF‑like growth factor; IGF‑II, insulin‑like growth factor II; EGFR, epidermal growth factor receptor; MAPK, mitogen‑activated protein kinase; AKT, 
protein kinase B or PKB; STAT3, signal transducer and activator of transcription 3; SRC, proto-oncogene tyrosine kinase SRC; IGF-IR, insulin-like growth 
fact) or 1 receptor.
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Discussion
Despite major advances in the early diagnosis and treatment 
of solid tumors in the past three decades, pancreatic cancer 
remains as one of the most aggressive and deadliest forms 
of cancer. By 2030, it is predicted to become the second 
leading cause of cancer-related deaths after lung cancer (31). 
Due to its heterogenous nature, its retroperitoneal location, 
non‑specific symptoms and lack of screening methods, the 
overwhelming majority of pancreatic cancer patients are 
diagnosed at an advanced stage of the disease at the time of 
presentation (32). To date, of the HER inhibitors, only the 
EGFR‑specific tyrosine kinase inhibitor (TKI), erlotinib has 
gained the FDA approval for the targeted therapy of locally 
advanced, unresectable or metastatic pancreatic cancer in 
combination with the cytotoxic agent gemcitabine (14). 
However, the majority of pancreatic cancer patients have 
either primary resistance, or develop seondary resistance 
following a short course of erlotinib. As a result, the duration 
of response can be short in many patients (7,30). Therefore, 
there is an urgent need to discover more effective therapeutic 
interventions for patients diagnosed with different stages of 
pancreatic cancer (7).
We previously demonstrated that of the pan HER family 
blocker, afatinib was more effective than erlotinib in inhib-
iting the growth of human pancreatic cancer cells (27). We 
also reported that treatment with afatinib in combination 
the insulin-like growth factor 1 receptor (IGF-IR) inhibitor 
NVP-AEW541 resulted in synergistic growth inhibition of 
pancreatic cancer cells (15). Due to the heterogeneous nature 
of pancreatic cancer, in this study we investigated the growth 
response of human pancreatic cancer cell lines (HPCCLs), 
established from patients at different stages of the disease, to 
the treatment with agents targeting different cyclin-dependent 
kinases (CDKs), various growth factor receptors and cell 
signaling molecules.
Of all the agents examined, the CDK1/2/5/9 inhibitor, 
dinaciclib was the most potent agent and inhibited the prolif-
eration of all seven primary and metastatic HPCCLs with IC50 
values of ≤10 nM. Pre‑clinical testing of dinaciclib exhibited 
an acceptable toxicity profile and effective inhibition in mouse 
models and it was found to be safe and well tolerated in 
phase I trials (33,34). The second most effective agent with 
anti-proliferative activity was the SRC/c-kit/Abl inhibitor 
dasatinib. It inhibited the growth of all seven primary and 
metastatic HPCCLs with IC50 of ≤258 nM). However, the most 
sensitive cell line to growth inbition by dasatinib were Bx-PC3 
and Mia‑PaCa‑2, which were established from two primary 
tumors and with IC50 values of 70 and 80 nM, respectively. 
The third most effective agent was the STAT3 inhibitor stattic 
which inhibited the growth of all HPCCLs with IC50 of ≤2 µM. 
The pan-HER family blocker also inhibited the growth of all 
seven HPCCLs with IC50 values ≤2.95 µM). However, the 
most sensitivite cell lines to treatment with afatinib were the 
EGFR, HER2 and HER3-positive BxPC-3 and CF-PAC1 cells 
whereas the reversible EGFR TKI erlotinib was only effective 
in BxPC-3, CF-PAC1 and Hs766T cells. We found a statisti-
cally significant association between HER3 expression and 
their response to treatment with TKIs targeting HER family 
members. In another study, Frolov and colleagues suggested 
that the higher sensitivity of HER3-positive cell lines to treat-
ment with pan-HER TKIs could be due to blockade of HER-3 
transactivation via EGFR therefore inhibiting PI3K/AKT 
signaling pathways (35). Other studies have also supported 
the association between the expression level of HER3 and 
the sensitivity of pancreatic cancer cell lines to treatment 
with erlotinib (35,36). Although our panel of cell lines was 
moderately positive for IGF-IR and showed moderate sensi-
tivity to agents targeting IGF‑IR and fibroblast growth factor 
receptor (FGFR), some statistically significant associations 
were found between IGF-IR expression and their response to 
treatment with HER family TKIs as well as HER2 expression 
and treatment with ALK/IGF-IR/InsR inhibitor ceritinib and 
FGFR inhibitor AZD4547. Both IGF-IR and FGFR-mediated 
signaling pathways have been found to participate in the 
resistance to anti‑HER targeted therapy (15,37,38). Moreover, 
we and other researchers have shown that the co-targeting of 
IGF-IR and HER family members results in synergistic growth 
inhibition of human pancreatic cancer cells (15,39).
The synchronous activation of bypass pathways via 
receptor tyrosine kinases (RTKs) including c‑MET and ALK7 
has been shown to induce resistance to current treatments and 
have emerged as important therapeutic targets for pancreatic 
cancer treatments. The expression level of both these receptors 
in our panel of cell lines was moderate. While the growth of 
all seven HPCCLs were inhibited by the dual c‑MET/ALK 
TKI crizotinib (i.e., IC50 values ≤3.3 µM), none of the cell 
lines were sensitive to treatment with the c‑MET‑specific TKI, 
capmatinib (i.e., IC50 values >10 µM). However, a significant 
association was found between c‑MET and ALK‑7 expression 
and their response to treatment with the STAT3 inhibitor stattic. 
STAT3 lies at the convergence of multiple oncogenic signaling 
pathways stimulated by upstream activated receptors such as 
c‑MET and ALK (19,40). A study reported that hyperactivated 
Table IV. Combination index (CI) values of dinaciclib plus afatinib, dasatinib plus afatinib and dasatinib plus gemcitabine in 
human pancreatic cancer cell lines.
 Dinaciclib + afatinib Afatinib + dasatinib Dasatinib + gemcitabine
Cell lines combination index (effect) combination index (effect) combination index (effect)
BxPC-3 1.32 (slight antagonism) 0.97 (nearly additive) 0.85 (moderate synergism)
Capan-1 1.85 (antagonism) 0.39 (synergism) 0.35 (synergism)
FA-6 1.60 (antagonism) 0.53 (synergism) 0.66 (synergism)
Mia‑Paca2 1.66 (antagonism) 0.58 (synergism) 0.85 (moderate synergism)
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Table V. Linear regression analysis of the expression of various receptors against the sensitivity of human pancreatic cancer cell 
lines to treatment with various TKIs, CDK inhibitors, STAT3 inhibitor and a cytotoxic agent.
Drugs/cell EGFR R2 HER2 R2 HER3 R2 IGF-IR R2 C‑MET R2 ALK7 R2
surface markers (P-value) (P-value) (P-value) (P-value) (P-value) (P-value)
Palbociclib 0.004 (0.895) 0.345 (0.165) 0.046 (0.646) 0.001 (0.940) 0.091 (0.511) 0.125 (0.437)
Crizotinib  0.203 (0.310) 0.185 (0.336) 0.230 (0.276) 0.017 (0.779) 0.158 (0.377) 0.029 (0.715)
Ceritinib  0.001 (0.948) 0.698 (0.019) 0.496 (0.077) 0.038 (0.674) 0.031 (0.704) 0.002 (0.916)
Brigatinib  0.184 (0.692) 0.180 (0.343) 0.132 (0.424) 0.069 (0.569) 0.031 (0.705) 0.021 (0.756)
Erlotinib  0.018 (0.772) 0.204 (0.309) 0.830 (0.004) 0.608 (0.039) 0.449 (0.100) 0.371 (0.147)
Afatinib  0.000 (0.965) 0.188 (0.331) 0.599 (0.041) 0.672 (0.024) 0.386 (0.137) 0.248 (0.256)
Gemcitabine  0.197 (0.318) 0.087 (0.522) 0.021 (0.785) 0.005 (0.882) 0.006 (0.865) 0.026 (0.732)
Dasatinib  0.231 (0.275) 0.034 (0.691) 0.105 (0.478) 0.007 (0.854) 0.268 (0.234) 0.020 (0.763)
Linsitinib  0.114 (0.459) 0.133 (0.421) 0.062 (0.589) 0.088 (0.519) 0.038 (0.674) 0.000 (0.972)
Stattic  0.232 (0.274) 0.008 (0.845) 0.483 (0.083) 0.412 (0.120) 0.809 (0.006) 0.682 (0.022)
Crenolanib  0.034 (0.694) 0.236 (0.269) 0.010 (0.828) 0.189 (0.329) 0.232 (0.274) 0.000 (0.983)
Bosutinib 0.003 (0.903) 0.020 (0.763) 0.355 (0.158) 0.074 (0.555) 0.747 (0.012) 0.397 (0.129)
AZD4547  0.001 (0.959) 0.751 (0.012) 0.063 (0.587) 0.053 (0.620) 0.054 (0.616) 0.040 (0.667)
Ponatinib 0.261 (0.241) 0.041 (0.663) 0.186 (0.334) 0.091 (0.512) 0.066 (0.577) 0.037 (0.681)
SPSS software was used to determine the significance and R2 value using linear regression analysis where the expression of cell surface 
marker was independent variable and IC50 value of the drug was the dependent variable. A R2 value closer to 1 indicated reliability of the data 
whereas P‑value of <0.05 was considered statistically significant (printed in bold). TKIs, tyrosine kinase inhibitors, CDK, cyclin‑dependent 
kinase; STAT3, signal transducer and activator of transcription 3; IC50, half maximal inhibitory concentration; EGFR, epidermal growth factor 
receptor; HER, human epidermal growth factor receptor; IGF-IR, insulin-like growth factor 1 receptor; ALK7, anaplastic lymphoma kinase 7.
Figure 5. Continued.
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STAT3 signaling in non-small cell lung cancer (NSCLC) 
was induced by the activation of MET (41). In addition, a 
significant association was found between c‑MET expression 
and Src/Abl inhibitor bosutinib. The SRC and Abl are some 
of the intracellular effector molecules recruited following 
auto‑phosphorylation of docking site of activated c‑MET (40). 
Overexpression and activation of the c‑MET receptor have 
been shown to be involved in SRC kinase activation (42).
Cell cycle distribution analysis revealed that the treatment 
of HPCCLs with afatinib, dasatinib, dinaciclib, stattic and 
gemcitabine increased the population of cells in sub-G1 with 
concomitant decrease in the G1 phase. Afatinib treatment also 
increased cells in the S and G2/M phase in most of the cell 
lines and similar results were reported following the treatment 
of nasopharyngeal carcinomas with afatinib (43). Dinaciclib 
treatment caused S-phase arrest in most of the cell lines which 
is consistent with the blockage of CDK2, one of the targets 
of dinaciclib (44). Treatment with dasatinib arrested cells 
in the S and G2/M phase which is consistent with a study 
where increasing the dasatinib concentration from 0.5‑1.0 µM 
increased the percentage of BxPC-3 cells in the S-phase (21). 
Treatment with the cytotoxic agent gemcitabine increased 
cells in S-phase consistent with the inhibition of DNA replica-
tion (45). Treatment with afatinib, dastainib and stattic inhibited 
the phophorylation of EGFR, SRC and STAT3, respectively 
and the migration of four human pancreatic cancer cell lines, 
established from patients with either a primary tumor or a 
meastatic tumor. Our results suggest that treatment with these 
agents result in inhibition of two hallmarks of cancer which 
are tumour cell proliferation and migration.
Next, we investigated the combinational potential of most 
effective drugs on four HPCCLs. We found that treatment 
with a combination of SRC targeting TKI dasatinib with 
the pan-HER TKI afatinib resulted in synergistic growth 
Figure 5. (A) Effect of selected agents on the migration of human pancreatic cancer cell lines at different time intervals. P<0.05 was considered significant; 
NS, not significant. (B) Effect of various agents on the migration of BxPC‑3 cells at 24 post treatment using scratch wound healing experiment.
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inhibition of all four HPCCLs examined. Treatment with the 
combination of dasatinib with gemcitabine also resulted in 
synergistic growth inhibition of four HPCCLs, including those 
established from patients with a primary pancreatic tumor 
(e.g., Bx-PC-3) or liver metastasis (e.g., Capan-1). Consistent 
with the results of a present study, the latter combination 
has been reported to have synergistic effect in two other 
HPCCLs (46,47). Although, dasatinib and gemcitabine combi-
nation has been shown to promote stable disease and to induce 
a partial response in patients with pancreatic cancer (48), it 
failed to improve patient survival in a phase II trial setting due 
to increased toxicity of such a combination (49). This combi-
nation is currently being used in a phase II trial in pancreatic 
cancer patients (ClinicalTrials.gov Identifier: NCT01234935). 
The triple combination of SRC inhibitor (dasatinib), EGFR 
inhibitor (erlotinib) and gemcitabine demonstrated a syner-
gistic antitumor effect in pancreatic ductal adenocarcinoma 
(PDAC) as well as encouraging preliminary activity in 
patients with advanced pancreatic cancer (50,51). However, 
when afatinib was used in combination with the CDK1/2/5/9 
inhibitor, dinaciclib, such a combination had agonistic effect 
in all cell lines examined. This highlights the importance of 
selecting the appropriate partner when such drugs are used in 
combination.
In conclusion, we demonstrated that of various targeting 
agents employed in our study, the CDK inhibitor dinaciclib, the 
irreversible pan-HER TKI afatinib, and the SRC targeting TKI 
dasatinib were most effective at inhibiting the proliferation 
and migration of HPCCLs, established from both a primary 
pancreatic cancer and from a metastatic pancreatic cancer. 
The combination of dasatinib with afatinib and dasatinib with 
gemcitabine led to synergistic growth inhibition in pancreatic 
cancer cell lines. Our results support the need for further 
investigation of the therapeutic potential of these combinations 
in the treatment of pancreatic cancer.
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